Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,029 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
You B, Purdy C, Copeland LJ, Swisher EM, Bookman MA, Fleming G, Coleman R, Randall LM, Tewari KS, Monk BJ, Mannel RS, Walker JL, Cappuccini F, Cohn D, Muzaffar M, Mutch D, Wahner-Hendrickson A, Martin L, Colomban O, Burger RA. You B, et al. Among authors: fleming g. J Clin Oncol. 2022 Dec 1;40(34):3965-3974. doi: 10.1200/JCO.22.01207. Epub 2022 Oct 17. J Clin Oncol. 2022. PMID: 36252167 Free PMC article. Clinical Trial.
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Gordon MS, et al. J Clin Oncol. 2006 Sep 10;24(26):4324-32. doi: 10.1200/JCO.2005.05.4221. Epub 2006 Aug 8. J Clin Oncol. 2006. PMID: 16896006 Clinical Trial.
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group. Burger RA, et al. N Engl J Med. 2011 Dec 29;365(26):2473-83. doi: 10.1056/NEJMoa1104390. N Engl J Med. 2011. PMID: 22204724 Free article. Clinical Trial.
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.
Fleming GF, Filiaci VL, Marzullo B, Zaino RJ, Davidson SA, Pearl M, Makker V, Burke JJ 2nd, Zweizig SL, Van Le L, Hanjani P, Downey G, Walker JL, Reyes HD, Leslie KK. Fleming GF, et al. Gynecol Oncol. 2014 Mar;132(3):585-92. doi: 10.1016/j.ygyno.2014.01.015. Epub 2014 Jan 20. Gynecol Oncol. 2014. PMID: 24456823 Free PMC article. Clinical Trial.
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.
Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX. Burger RA, et al. J Clin Oncol. 2014 Apr 20;32(12):1210-7. doi: 10.1200/JCO.2013.53.6524. Epub 2014 Mar 17. J Clin Oncol. 2014. PMID: 24637999 Free PMC article. Clinical Trial.
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
Ferriss JS, Java JJ, Bookman MA, Fleming GF, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente MP, Burger RA. Ferriss JS, et al. Gynecol Oncol. 2015 Oct;139(1):17-22. doi: 10.1016/j.ygyno.2015.07.103. Epub 2015 Jul 26. Gynecol Oncol. 2015. PMID: 26216729 Free PMC article. Clinical Trial.
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.
von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, Rutherford TJ, Higgins RV, Secord AA, Fleming G. von Gruenigen VE, et al. Among authors: fleming g. Gynecol Oncol. 2017 Mar;144(3):459-467. doi: 10.1016/j.ygyno.2016.11.033. Epub 2017 Jan 13. Gynecol Oncol. 2017. PMID: 28089376 Free PMC article.
High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.
Reyes HD, Miecznikowski J, Gonzalez-Bosquet J, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Stephan JM, Hanjani P, Guntupalli S, Tewari KS, Backes F, Ramirez N, Fleming GF, Filiaci V, Birrer MJ, Leslie KK. Reyes HD, et al. Gynecol Oncol. 2017 Aug;146(2):247-253. doi: 10.1016/j.ygyno.2017.05.017. Epub 2017 May 19. Gynecol Oncol. 2017. PMID: 28532857 Free PMC article.
1,029 results